Flublok is our seasonal influenza vaccine candidate, made using our BEVS platform technology.

We have completed Phase III clinical trials for Flublok, and a Biologics License Application (BLA) for its commercialization is under final review at the FDA.

Flublok is comprised of purified recombinant hemagglutinin antigens. Hemagglutinin is a protein expressed on the surface of influenza viruses that is strain-specific (for example, the H1 in H1N1). Flublok is tailored annually to provide protection against the latest strains of influenza by containing the corresponding hemagglutinin antigens for those strains. Because Flublok is made using recombinant technology (i.e., without the use of actual influenza virus), there is no risk of getting the flu from the vaccine.

Flublok is formulated to contain 3X the active ingredients in widely available influenza vaccines. In addition, because it is not made in eggs, Flublok is safe for individuals with egg-related allergies.

Influenza is a leading cause of illness and death around the world, resulting on average in more than 200,000 hospitalizations and ranging from 3,000 to 49,000 deaths annually in the U.S. alone. More than 90% of influenza-related deaths occur in people over the age of 65, and individuals of all ages with weakened immune systems are at particularly high risk for developing complications from the illness. Available vaccines have a limited ability to protect these populations. Clinical trials with Flublok suggest that it is more effective at generating protective antibody titers against influenza in elderly and immune-compromised individuals compared to a licensed vaccine.

Flublok Advantages:

Higher antigen content

Potentially superior immunogenicity for the elderly and immune-compromised

Manufacturing platform requires less lead time, allowing regulators more time to make accurate flu response decisions

No influenza viruses used in production

No antibiotics, adjuvants or preservatives (e.g., thimerosal)

No egg-related byproducts

For more information on influenza and the safety and efficacy of vaccines, click here.